These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38429657)

  • 1. Few-shot genes selection: subset of PAM50 genes for breast cancer subtypes classification.
    Okimoto LYS; Mendonca-Neto R; Nakamura FG; Nakamura EF; Fenyö D; Silva CT
    BMC Bioinformatics; 2024 Mar; 25(1):92. PubMed ID: 38429657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research-based PAM50 signature and long-term breast cancer survival.
    Pu M; Messer K; Davies SR; Vickery TL; Pittman E; Parker BA; Ellis MJ; Flatt SW; Marinac CR; Nelson SH; Mardis ER; Pierce JP; Natarajan L
    Breast Cancer Res Treat; 2020 Jan; 179(1):197-206. PubMed ID: 31542876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel secretome-to-transcriptome integrated or secreto-transcriptomic approach to reveal liquid biopsy biomarkers for predicting individualized prognosis of breast cancer patients.
    Ankney JA; Xie L; Wrobel JA; Wang L; Chen X
    BMC Med Genomics; 2019 May; 12(1):78. PubMed ID: 31146747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCA-PAM50 improves consistency between breast cancer intrinsic and clinical subtyping reclassifying a subset of luminal A tumors as luminal B.
    Raj-Kumar PK; Liu J; Hooke JA; Kovatich AJ; Kvecher L; Shriver CD; Hu H
    Sci Rep; 2019 May; 9(1):7956. PubMed ID: 31138829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.
    Wallden B; Storhoff J; Nielsen T; Dowidar N; Schaper C; Ferree S; Liu S; Leung S; Geiss G; Snider J; Vickery T; Davies SR; Mardis ER; Gnant M; Sestak I; Ellis MJ; Perou CM; Bernard PS; Parker JS
    BMC Med Genomics; 2015 Aug; 8():54. PubMed ID: 26297356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series.
    Picornell AC; Echavarria I; Alvarez E; López-Tarruella S; Jerez Y; Hoadley K; Parker JS; Del Monte-Millán M; Ramos-Medina R; Gayarre J; Ocaña I; Cebollero M; Massarrah T; Moreno F; García Saenz JA; Gómez Moreno H; Ballesteros A; Ruiz Borrego M; Perou CM; Martin M
    BMC Genomics; 2019 Jun; 20(1):452. PubMed ID: 31159741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-Omic Regulation of the PAM50 Gene Signature in Breast Cancer Molecular Subtypes.
    Ochoa S; de Anda-Jáuregui G; Hernández-Lemus E
    Front Oncol; 2020; 10():845. PubMed ID: 32528899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A deep learning image-based intrinsic molecular subtype classifier of breast tumors reveals tumor heterogeneity that may affect survival.
    Jaber MI; Song B; Taylor C; Vaske CJ; Benz SC; Rabizadeh S; Soon-Shiong P; Szeto CW
    Breast Cancer Res; 2020 Jan; 22(1):12. PubMed ID: 31992350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtyping for clinically defined breast cancer subgroups.
    Zhao X; Rødland EA; Tibshirani R; Plevritis S
    Breast Cancer Res; 2015 Feb; 17(1):29. PubMed ID: 25849221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.
    Klopfenstein Q; Derangère V; Arnould L; Thibaudin M; Limagne E; Ghiringhelli F; Truntzer C; Ladoire S
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Discovery of Novel Biomarkers Improves Breast Cancer Intrinsic Subtype Prediction and Reconciles the Labels in the METABRIC Data Set.
    Milioli HH; Vimieiro R; Riveros C; Tishchenko I; Berretta R; Moscato P
    PLoS One; 2015; 10(7):e0129711. PubMed ID: 26132585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications.
    Allott EH; Shan Y; Chen M; Sun X; Garcia-Recio S; Kirk EL; Olshan AF; Geradts J; Earp HS; Carey LA; Perou CM; Pfeiffer RM; Anderson WF; Troester MA
    Breast Cancer Res Treat; 2020 Jan; 179(1):185-195. PubMed ID: 31535320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mixture classification model based on clinical markers for breast cancer prognosis.
    Zeng T; Liu J
    Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
    Lopez-Tarruella S; Del Monte-Millán M; Roche-Molina M; Jerez Y; Echavarria Diaz-Guardamino I; Herrero López B; Gamez Casado S; Marquez-Rodas I; Alvarez E; Cebollero M; Massarrah T; Ocaña I; Arias A; García-Sáenz JÁ; Moreno Anton F; Olier Garate C; Moreno Muñoz D; Marrupe D; Lara Álvarez MÁ; Enrech S; Bueno Muiño C; Martín M
    Breast Cancer Res Treat; 2024 Jan; 203(1):163-172. PubMed ID: 37773555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and methylation patterns partition luminal-A breast tumors into distinct prognostic subgroups.
    Netanely D; Avraham A; Ben-Baruch A; Evron E; Shamir R
    Breast Cancer Res; 2016 Jul; 18(1):74. PubMed ID: 27386846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-driven integrated classification of breast cancer validated in over 7,500 samples.
    Ali HR; Rueda OM; Chin SF; Curtis C; Dunning MJ; Aparicio SA; Caldas C
    Genome Biol; 2014 Aug; 15(8):431. PubMed ID: 25164602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of subtype-specific breast cancer surface protein biomarkers via a novel transcriptomics approach.
    Mercatelli D; Formaggio F; Caprini M; Holding A; Giorgi FM
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34750607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics.
    Sweeney C; Bernard PS; Factor RE; Kwan ML; Habel LA; Quesenberry CP; Shakespear K; Weltzien EK; Stijleman IJ; Davis CA; Ebbert MT; Castillo A; Kushi LH; Caan BJ
    Cancer Epidemiol Biomarkers Prev; 2014 May; 23(5):714-24. PubMed ID: 24521995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.